Ole Andersen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ole Andersen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Annemette Palmqvist
Department of Science and Environment, Roskilde University, Universitetsvej 1, PO Box 260, 4000 Roskilde, Denmark
1 shared publication Astrid Petersen
Department of Pathology, Aalborg University Hospital, Aalborg, Denmark
1 shared publication- Bjarne Styrishave
Drug Toxicology, Metabolism and Analysis Group, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen OE, Denmark
1 shared publication Bolette Danckert
Director´s Office, Danish Cancer Society Research Center, Copenhagen, Denmark
1 shared publicationChristian B.I. Andersen
1 shared publication- Frede Donskov
Department of Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark
1 shared publication
Latest Publications
- 15 January 2022
- Published by Elsevier
- p. 593-627
Ecotoxicology of metals—sources, transport, and effects on the ecosystem
- 15 January 2022
- Published by Elsevier
- p. 593-627
Ecotoxicology of metals—sources, transport, and effects on the ecosystem
- 1 October 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (35) , 7238-7246
Clinical Therapy of Patients Contaminated with Polonium or Plutonium
Although most of the harmful radionuclides are of anthropogenic origin and released from military or industrial processes, radioactive substances, such as uranium, also occur naturally in the environment. Low standards of care at nuclear facilities can lead to the contamination of employees with radionuclides due to inhalation of gases or dust or contamination of skin or wounds. Various sources for radionuclide exposure may present concerns for radioactive polonium or plutonium exposure, for instance, terrorist actions on the infrastructure, such as on drinking water basins. Early health effects after extensive radiation exposure may be vomiting, headaches, and fatigue, followed by bone marrow depression, fever, and diarrhea. The main purpose of radionuclide mobilization is to minimize the radiation dose. Since some of the important radionuclides, such as polonium and plutonium, have very long biological half-times after their deposition in bone, liver or kidneys, rapid initiation of chelation treatment is usually imperative after a contamination event. The antidote DMPS (dimercapto-propanesulfonate) is considered the drug of choice for polonium decorporation. DTPA (diethylenetriamine pentaacetate) is a potent chelator especially approved for radionuclide mobilization, including polonium and other actinides. Other chelators and drugs are under investigation as potential chelators of transuranic elements.
- 1 October 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (35) , 7238-7246
Clinical Therapy of Patients Contaminated with Polonium or Plutonium
Although most of the harmful radionuclides are of anthropogenic origin and released from military or industrial processes, radioactive substances, such as uranium, also occur naturally in the environment. Low standards of care at nuclear facilities can lead to the contamination of employees with radionuclides due to inhalation of gases or dust or contamination of skin or wounds. Various sources for radionuclide exposure may present concerns for radioactive polonium or plutonium exposure, for instance, terrorist actions on the infrastructure, such as on drinking water basins. Early health effects after extensive radiation exposure may be vomiting, headaches, and fatigue, followed by bone marrow depression, fever, and diarrhea. The main purpose of radionuclide mobilization is to minimize the radiation dose. Since some of the important radionuclides, such as polonium and plutonium, have very long biological half-times after their deposition in bone, liver or kidneys, rapid initiation of chelation treatment is usually imperative after a contamination event. The antidote DMPS (dimercapto-propanesulfonate) is considered the drug of choice for polonium decorporation. DTPA (diethylenetriamine pentaacetate) is a potent chelator especially approved for radionuclide mobilization, including polonium and other actinides. Other chelators and drugs are under investigation as potential chelators of transuranic elements.
- Open Access
- 1 July 2020
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 12, 807-814
Registrations of Patients with Renal Cell Carcinoma in the Nationwide Danish Renal Cancer Database versus the Danish Cancer Registry: Data Quality, Completeness and Survival (DaRenCa Study-3)
Background: The Danish multidisciplinary renal cancer group (DaRenCa) established the nationwide database DaRenCaData in 2010. The Danish Cancer Registry (DCR) has been considered the golden standard. In contrast to DCR, DaRenCaData required the diagnosis to be histologically or cytologically verified. DaRenCaData and DCR have not previously been compared. Patients and Methods: We included patients with renal cell carcinoma registered in DaRenCaData and/or DCR from August 1st 2010 to December 31st 2015. We computed completeness and positive predictive value (PPV) of a diagnosis in DaRenCaData compared with DCR, 1-year, 3-year and 5-year mortality rate ratios, and relative survival. Results: We identified 4890 patients in the two registries. Of these, 4326 were registered in DaRenCaData and 4714 in DCR. Completeness of DaRenCaData was 88% [95% CI, 87– 89%] and increased during the period from 82% to 94%. The PPV was 96% [95% CI, 95– 97%]. A total of 4150 patients (85%) were found in both registries, 4% (176 patients) in DaRenCaData only, and 12% (564 patients) in DCR only. The relative survival was higher for patients in DaRenCaData vs DCR; the 1-year and 5-year relative survival was 85% vs 81% and 65% vs 59%, respectively. Compared with patients registered in both registries, the mortality rates were higher in patients registered in DaRenCaData only (1-year hazard ratio (HR)=2.84 [95% CI, 2.20– 3.68]) or DCR only (1-year HR=4.29 [95% CI, 3.72– 4.93]). Observed in both registries, survival improved over time with a 7% yearly reduction in death based on estimations of 1-year mortality rate ratios. Conclusion: DaRenCaData had high and increasing completeness and high PPV, establishing it as a high-quality research database. Observed in both registries, renal cell carcinoma mortality declined over time; patients only registered in DCR or DaRenCaData had poorer outcomes. This study points to the importance of assessing the inclusion criteria when interpreting registry-based studies.
- 1 July 2020
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 12, 807-814
Open AccessRegistrations of Patients with Renal Cell Carcinoma in the Nationwide Danish Renal Cancer Database versus the Danish Cancer Registry: Data Quality, Completeness and Survival (DaRenCa Study-3)
Background: The Danish multidisciplinary renal cancer group (DaRenCa) established the nationwide database DaRenCaData in 2010. The Danish Cancer Registry (DCR) has been considered the golden standard. In contrast to DCR, DaRenCaData required the diagnosis to be histologically or cytologically verified. DaRenCaData and DCR have not previously been compared. Patients and Methods: We included patients with renal cell carcinoma registered in DaRenCaData and/or DCR from August 1st 2010 to December 31st 2015. We computed completeness and positive predictive value (PPV) of a diagnosis in DaRenCaData compared with DCR, 1-year, 3-year and 5-year mortality rate ratios, and relative survival. Results: We identified 4890 patients in the two registries. Of these, 4326 were registered in DaRenCaData and 4714 in DCR. Completeness of DaRenCaData was 88% [95% CI, 87– 89%] and increased during the period from 82% to 94%. The PPV was 96% [95% CI, 95– 97%]. A total of 4150 patients (85%) were found in both registries, 4% (176 patients) in DaRenCaData only, and 12% (564 patients) in DCR only. The relative survival was higher for patients in DaRenCaData vs DCR; the 1-year and 5-year relative survival was 85% vs 81% and 65% vs 59%, respectively. Compared with patients registered in both registries, the mortality rates were higher in patients registered in DaRenCaData only (1-year hazard ratio (HR)=2.84 [95% CI, 2.20– 3.68]) or DCR only (1-year HR=4.29 [95% CI, 3.72– 4.93]). Observed in both registries, survival improved over time with a 7% yearly reduction in death based on estimations of 1-year mortality rate ratios. Conclusion: DaRenCaData had high and increasing completeness and high PPV, establishing it as a high-quality research database. Observed in both registries, renal cell carcinoma mortality declined over time; patients only registered in DCR or DaRenCaData had poorer outcomes. This study points to the importance of assessing the inclusion criteria when interpreting registry-based studies.
- 30 September 2015
- Published by Oxford University Press (OUP) in Environmental Toxicology and Chemistry
- Vol. 35 (2) , 394-404
Deciphering mechanisms of malathion toxicity under pulse exposure of the freshwater cladoceranDaphnia magna
The organophosphate pesticide (OP) malathion is highly toxic to freshwater invertebrates, including the cladoceran Daphnia magna, a widely used test organism in ecotoxicology. To assess whether toxic effects of malathion are driven primarily by exposure concentration or exposure duration, D. magna was pulse exposed to equivalent integrated doses (duration × concentration): 3 h × 16 μg/L, 24 h × 2 μg/L, and 48 h × 1 μg/L. After recovery periods of 3 h, 24 h, and 48 h, the toxicity of malathion on different biological levels in D. magna was examined by analyzing the following endpoints: survival and immobilization; enzyme activities of acetylcholinesterase (AChE), carboxylesterase (CbE), and glutathione S-transferase (GST); and AChE gene expression. The results showed no difference in survival among equivalent integrated doses. Adverse sublethal effects were driven by exposure concentration rather than pulse duration. Specifically, short pulse exposure to a high concentration of malathion resulted in more immobilized daphnids, lower AChE and CbE activities, and a higher transcript level of AChE gene compared with long pulse exposure to low concentration. The expression of the AChE gene was up-regulated, indicating a compensatory mechanism to cope with enzyme inhibition. The study shows the need for obtaining a better understanding of the processes underlying toxicity under realistic exposure scenarios, so this can be taken into account in environmental risk assessment of pesticides. Environ Toxicol Chem 2016;35:394–404. © 2015 SETAC
- 30 September 2015
- Published by Oxford University Press (OUP) in Environmental Toxicology and Chemistry
- Vol. 35 (2) , 394-404
Deciphering mechanisms of malathion toxicity under pulse exposure of the freshwater cladoceranDaphnia magna
The organophosphate pesticide (OP) malathion is highly toxic to freshwater invertebrates, including the cladoceran Daphnia magna, a widely used test organism in ecotoxicology. To assess whether toxic effects of malathion are driven primarily by exposure concentration or exposure duration, D. magna was pulse exposed to equivalent integrated doses (duration × concentration): 3 h × 16 μg/L, 24 h × 2 μg/L, and 48 h × 1 μg/L. After recovery periods of 3 h, 24 h, and 48 h, the toxicity of malathion on different biological levels in D. magna was examined by analyzing the following endpoints: survival and immobilization; enzyme activities of acetylcholinesterase (AChE), carboxylesterase (CbE), and glutathione S-transferase (GST); and AChE gene expression. The results showed no difference in survival among equivalent integrated doses. Adverse sublethal effects were driven by exposure concentration rather than pulse duration. Specifically, short pulse exposure to a high concentration of malathion resulted in more immobilized daphnids, lower AChE and CbE activities, and a higher transcript level of AChE gene compared with long pulse exposure to low concentration. The expression of the AChE gene was up-regulated, indicating a compensatory mechanism to cope with enzyme inhibition. The study shows the need for obtaining a better understanding of the processes underlying toxicity under realistic exposure scenarios, so this can be taken into account in environmental risk assessment of pesticides. Environ Toxicol Chem 2016;35:394–404. © 2015 SETAC
- Open Access
- 1 April 2012
- Published by Elsevier in Marine Environmental Research
- Vol. 75, 45-53
PAH biomarkers in common eelpout (Zoarces viviparus) from Danish waters
- 1 April 2012
- Published by Elsevier in Marine Environmental Research
- Vol. 75, 45-53
Open AccessPAH biomarkers in common eelpout (Zoarces viviparus) from Danish waters
- 1 March 2008
- Published by Cambridge University Press (CUP) in Journal of the Marine Biological Association of the United Kingdom
- Vol. 88 (3) , 575-581
Ecdysteroids in female shore crabs Carcinus maenas during the moulting cycle and oocyte development
The ecdysteroids ecdysone (E), 20-hydroxyecdysone (20E) and ponasterone A (PoA) were measured in the haemolymph, hepatopancreas and oocytes of female shore crabs Carcinus maenas during the moulting cycle and during oocyte maturation using HPLC-MS. In the haemolymph, ecdysteroid titres varied over the moulting cycle with high levels during premoult and low levels during postmoult and intermoult, however, no significant change in haemolymph ecdysteroid titres was observed in relation to oocyte development. In the hepatopancreas, PoA levels were high during premoult but low during postmoult and intermoult. This is in contrast to E and 20E where levels remained high from early intermoult (C1) until late premoult (D3) and only decreased during postmoult. In the oocytes, ecdysteroid levels were low during postmoult and for 20E and PoA also during late premoult D2 and D3. In contrast, all three ecdysteroids were observed to increase in the oocytes during oocyte development, in particular E and PoA. The present study demonstrates that changes in haemolymph ecdysteroid titres relate to changes in moulting status and not to changes in oocyte development. Also, the study indicates that the hepatopancreas is involved in the metabolism of ecdysteroids related to the moulting cycle but may also be involved in ecdysteroid metabolism during oocyte development. Furthermore, the pronounced increase in oocyte ecdysteroids during oocyte development during periods where haemolymph ecdysteroids titre is low, indicates that the oocytes are capable of de novo synthesis of the three ecdysteroids investigated.
- 1 March 2008
- Published by Cambridge University Press (CUP) in Journal of the Marine Biological Association of the United Kingdom
- Vol. 88 (3) , 575-581
Ecdysteroids in female shore crabs Carcinus maenas during the moulting cycle and oocyte development
The ecdysteroids ecdysone (E), 20-hydroxyecdysone (20E) and ponasterone A (PoA) were measured in the haemolymph, hepatopancreas and oocytes of female shore crabs Carcinus maenas during the moulting cycle and during oocyte maturation using HPLC-MS. In the haemolymph, ecdysteroid titres varied over the moulting cycle with high levels during premoult and low levels during postmoult and intermoult, however, no significant change in haemolymph ecdysteroid titres was observed in relation to oocyte development. In the hepatopancreas, PoA levels were high during premoult but low during postmoult and intermoult. This is in contrast to E and 20E where levels remained high from early intermoult (C1) until late premoult (D3) and only decreased during postmoult. In the oocytes, ecdysteroid levels were low during postmoult and for 20E and PoA also during late premoult D2 and D3. In contrast, all three ecdysteroids were observed to increase in the oocytes during oocyte development, in particular E and PoA. The present study demonstrates that changes in haemolymph ecdysteroid titres relate to changes in moulting status and not to changes in oocyte development. Also, the study indicates that the hepatopancreas is involved in the metabolism of ecdysteroids related to the moulting cycle but may also be involved in ecdysteroid metabolism during oocyte development. Furthermore, the pronounced increase in oocyte ecdysteroids during oocyte development during periods where haemolymph ecdysteroids titre is low, indicates that the oocytes are capable of de novo synthesis of the three ecdysteroids investigated.